Navigation Links
Added benefit of saxagliptin/metformin combination is not proven
Date:4/29/2013

>Regarding the combination with insulin, the manufacturer submitted a study that directly compared saxagliptin/metformin and insulin with metformin und human insulin. But the results of this study cannot be used for the assessment of the added benefit.

The main reason for this is that the insulin therapy could not be tailored sufficiently to the individual patient in the first treatment phase: even though their current insulin therapy was insufficient, patients were neither supposed to change the insulin nor to adapt the dose. But to be able to draw conclusions about the added benefit, the combination of saxagliptin/metformin and insulin would have to be compared with other strategies for optimizing treatment, for example optimizing insulin use.

Not tailoring treatment to the individual patient does not meet the current standard of diabetological practice anyway. Instead, insulin therapy is optimized for the individual patient so that hyperglycaemia and hypoglycaemia do not occur in the first place. So in the study, insulin was not used in a way that would be necessary and appropriate in this indication.

Therefore, there are no study results for either of the two therapeutic indications of the fixed combination saxagliptin/metformin from which an added benefit could be derived.

G-BA decides on the extent of added benefit

The dossier assessment is part of the overall procedure for early benefit assessments supervised by the G-BA. After publication of the manufacturer's dossier and IQWiG's assessment, the G-BA conducts a commenting procedure, which may provide further information and result in a change to the benefit assessment. The G-BA then decides on the extent of the added benefit, thus completing the early benefit assessment.


'/>"/>

Contact: Anna-Sabine Ernst
presse@iqwig.de
49-022-135-6850
Institute for Quality and Efficiency in Health Care
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Left Coast Marijuana Delivery Service Added To Top-Tier Dispensary Locator
2. BPA Added To California’s Toxic Chemicals List Making BPA-Free Dental Products from PureLife More Attractive
3. Astro-Clairvoyant Norah Guide With Premium Astrology Extends Blog Series With Newly Added Video Features
4. New Karlsson Vintage Wall Clocks Added at Contemporary Heaven
5. Innovative Medical Marijuana Growing Product added to PotLocator.com Lineup
6. Master Numerologist at Numerology Secret Added New Rave Reviews To His Testimonial Base
7. New Lines Added to the Arti & Mestieri Clocks Range at Contemporary Heaven US
8. Perampanel for epilepsy: No proof of added benefit
9. Added benefit of aclidinium bromide is not proven
10. Linagliptin: Once again, no proof of added benefit
11. New Wall Clocks Added to the Balvi Range at Contemporary Heaven
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... Concorde Career College North Hollywood ... the 2014 Excellence in Community Service Award from ... (ACCSC). , Every year, the Accrediting Commission of ... make outstanding contributions in their local community through ... scope and impact of the community service and ...
(Date:9/2/2014)... ROCHESTER, Minn. How well patients recover from ... their medical conditions and the operations themselves. Family ... risk of surgical complications, a Mayo Clinic study ... operation may reduce patients, stress, speed their recoveries ... The study specifically looked at colon cancer patients, ...
(Date:9/2/2014)... in their work care for patients who are dying. ... that many nurses in training feel unprepared and anxious ... end-of-life care. , Scientists from the Sahlgrenska Academy have ... the University of Skvde and the Ersta Skndal University ... for dying patients, their ideas about how to support ...
(Date:9/2/2014)... 02, 2014 Nanomedicine is essentially ... diagnosing, treating and/or prevention of diseases and infections. ... cardiovascular, neurological, and oncology diseases. , Nanomedicine ... to various nanoparticles, their medical usages, and their ... considerable scope for research in this domain, and ...
(Date:9/2/2014)... September 02, 2014 The performance of ... over the past five years. Industry revenue is estimated ... over the five years through 2014-15, following stabilised growth ... increasing external competition from alternate forms of gambling. Horse ... online gambling platforms have all become increasingly popular over ...
Breaking Medicine News(10 mins):Health News:Concorde Career College North Hollywood Awarded 2014 Excellence in Community Service Award 2Health News:Family conflicts, other non-physical worries before cancer surgery raise patients' complication risk 2Health News:Many nurses unprepared to meet dying patients 2Health News:Nanomedicine Market: An Overview of Growth Factors and Future Prospects by Transparency Market Research 2Health News:Nanomedicine Market: An Overview of Growth Factors and Future Prospects by Transparency Market Research 3Health News:Lotteries in Australia Industry Market Research Report Now Updated by IBISWorld 2Health News:Lotteries in Australia Industry Market Research Report Now Updated by IBISWorld 3
... Shengtai Pharmaceutical, Inc. (OTC,Bulletin Board: SGTI) ("Shengtai Pharmaceutical" ... high-quality, pharmaceutical grade,glucose products in China, today reported ... 2007., Second Quarter of Fiscal 2008 ... $25.0 million -- Gross profit rose 91% ...
... treatments for the disease, study suggests , , THURSDAY, Feb. 14 ... cells into mice with hemophilia enables the animals to produce ... hemophilia. , The breakthrough finding may lead the way to ... of the disease, researchers believe. , "We were able to ...
... /PRNewswire-FirstCall/ - NUCRYST,Pharmaceuticals Corp. (NASDAQ: NCST ; TSX: ... 2007. Net loss narrowed to $4.0 million, or 22,cents ... to a net loss,of $10.5 million, or 58 cents ... year. The lower net loss for 2007 is primarily ...
... MONTREAL, Feb. 14 /PRNewswire-FirstCall/ - CryoCath(R) Technologies,Inc., the ... announced financial results for the first quarter, ended,December 31, ... Highlights: - EP Revenue for Q1 2008 ... over Q1 2007. All regions around ...
... people,through the U.S. Agency for International Development (USAID), ... Tajikistan after extreme winter weather,and an energy crisis ... This,funding will help provide fuel, heaters, clothing, household ... USAID partners Save the Children,CARE, and Mercy Corps., ...
... 14 Today, Lung Cancer,Alliance announced that for the ... called for a screening program for veterans at high,risk ... USN, (Ret.), chairman of LCA,s Board of,Directors said today, ... these organizations for speaking out about the number one,cancer ...
Cached Medicine News:Health News:Shengtai Pharmaceutical, Inc. Reports Strong Second Quarter Results of Fiscal Year 2008 2Health News:Shengtai Pharmaceutical, Inc. Reports Strong Second Quarter Results of Fiscal Year 2008 3Health News:Shengtai Pharmaceutical, Inc. Reports Strong Second Quarter Results of Fiscal Year 2008 4Health News:Shengtai Pharmaceutical, Inc. Reports Strong Second Quarter Results of Fiscal Year 2008 5Health News:Shengtai Pharmaceutical, Inc. Reports Strong Second Quarter Results of Fiscal Year 2008 6Health News:Shengtai Pharmaceutical, Inc. Reports Strong Second Quarter Results of Fiscal Year 2008 7Health News:Shengtai Pharmaceutical, Inc. Reports Strong Second Quarter Results of Fiscal Year 2008 8Health News:Shengtai Pharmaceutical, Inc. Reports Strong Second Quarter Results of Fiscal Year 2008 9Health News:Shengtai Pharmaceutical, Inc. Reports Strong Second Quarter Results of Fiscal Year 2008 10Health News:Shengtai Pharmaceutical, Inc. Reports Strong Second Quarter Results of Fiscal Year 2008 11Health News:Shengtai Pharmaceutical, Inc. Reports Strong Second Quarter Results of Fiscal Year 2008 12Health News:Transplanted Liver Lining Cells May Cure Hemophilia 2Health News:NUCRYST Pharmaceuticals announces year-end results 2Health News:NUCRYST Pharmaceuticals announces year-end results 3Health News:NUCRYST Pharmaceuticals announces year-end results 4Health News:NUCRYST Pharmaceuticals announces year-end results 5Health News:NUCRYST Pharmaceuticals announces year-end results 6Health News:NUCRYST Pharmaceuticals announces year-end results 7Health News:NUCRYST Pharmaceuticals announces year-end results 8Health News:NUCRYST Pharmaceuticals announces year-end results 9Health News:NUCRYST Pharmaceuticals announces year-end results 10Health News:NUCRYST Pharmaceuticals announces year-end results 11Health News:NUCRYST Pharmaceuticals announces year-end results 12Health News:CryoCath Announces Fiscal 2008 First Quarter Results 2Health News:CryoCath Announces Fiscal 2008 First Quarter Results 3Health News:CryoCath Announces Fiscal 2008 First Quarter Results 4Health News:CryoCath Announces Fiscal 2008 First Quarter Results 5Health News:CryoCath Announces Fiscal 2008 First Quarter Results 6Health News:CryoCath Announces Fiscal 2008 First Quarter Results 7Health News:CryoCath Announces Fiscal 2008 First Quarter Results 8Health News:CryoCath Announces Fiscal 2008 First Quarter Results 9Health News:CryoCath Announces Fiscal 2008 First Quarter Results 10Health News:CryoCath Announces Fiscal 2008 First Quarter Results 11Health News:Veterans Organizations Call for Lung Cancer Screening 2Health News:Veterans Organizations Call for Lung Cancer Screening 3
(Date:9/2/2014)... -- Cyberonics, Inc. (NASDAQ: CYBX ), today ... of the study presented by a prominent heart ... and concurrently published by the Journal of ... in patients with moderate to severe chronic heart ... the heart,s ability to pump blood, and reduces ...
(Date:9/2/2014)... , Sept. 2, 2014  Abaxis, Inc. (NasdaqGS: ... point-of-care blood instrumentation and consumables to the medical, research ... , Chairman and Chief Executive Officer, will present at ... 10, 2014 at 10:20 a.m. ET. The conference will ... New York City . ...
(Date:9/2/2014)...  Hologic, Inc. (NASDAQ: HOLX ) today announced ... will present at the Morgan Stanley Global Healthcare Conference in ... York on Tuesday, September 9, 2014 at 12:20 ... listen to the live audio webcast of the presentation on ... An archive of the presentation will be available for replay ...
Breaking Medicine Technology:ANTHEM-HF Shows Autonomic Regulation Therapy Is Safe And Improves Heart Function In Patients With Chronic Heart Failure 2ANTHEM-HF Shows Autonomic Regulation Therapy Is Safe And Improves Heart Function In Patients With Chronic Heart Failure 3ANTHEM-HF Shows Autonomic Regulation Therapy Is Safe And Improves Heart Function In Patients With Chronic Heart Failure 4ANTHEM-HF Shows Autonomic Regulation Therapy Is Safe And Improves Heart Function In Patients With Chronic Heart Failure 5Abaxis, Inc. to Present at the Morgan Stanley Global Healthcare Conference 2
... Reportlinker.com announces that a new market research report ... European Markets for Interventional Cardiology Devices 2011 ... In 2010, the European markets ... euro1.5 billion. In 2010, the fastest growing European ...
... MOUNTAIN VIEW, Calif., April 7, 2011 /PRNewswire/ -- ... today announced the publication of results from the Phase ... in the peer-reviewed journal ,Headache., The manuscript, titled MAP0004, ... Acute Treatment of Migraine, has been posted online and ...
Cached Medicine Technology:Reportlinker Adds European Markets for Interventional Cardiology Devices 2011 (15 Countries) 2Reportlinker Adds European Markets for Interventional Cardiology Devices 2011 (15 Countries) 3Reportlinker Adds European Markets for Interventional Cardiology Devices 2011 (15 Countries) 4Reportlinker Adds European Markets for Interventional Cardiology Devices 2011 (15 Countries) 5Reportlinker Adds European Markets for Interventional Cardiology Devices 2011 (15 Countries) 6Reportlinker Adds European Markets for Interventional Cardiology Devices 2011 (15 Countries) 7Reportlinker Adds European Markets for Interventional Cardiology Devices 2011 (15 Countries) 8Reportlinker Adds European Markets for Interventional Cardiology Devices 2011 (15 Countries) 9Reportlinker Adds European Markets for Interventional Cardiology Devices 2011 (15 Countries) 10Reportlinker Adds European Markets for Interventional Cardiology Devices 2011 (15 Countries) 11Reportlinker Adds European Markets for Interventional Cardiology Devices 2011 (15 Countries) 12Reportlinker Adds European Markets for Interventional Cardiology Devices 2011 (15 Countries) 13Reportlinker Adds European Markets for Interventional Cardiology Devices 2011 (15 Countries) 14Reportlinker Adds European Markets for Interventional Cardiology Devices 2011 (15 Countries) 15Reportlinker Adds European Markets for Interventional Cardiology Devices 2011 (15 Countries) 16Reportlinker Adds European Markets for Interventional Cardiology Devices 2011 (15 Countries) 17Reportlinker Adds European Markets for Interventional Cardiology Devices 2011 (15 Countries) 18Reportlinker Adds European Markets for Interventional Cardiology Devices 2011 (15 Countries) 19Reportlinker Adds European Markets for Interventional Cardiology Devices 2011 (15 Countries) 20Reportlinker Adds European Markets for Interventional Cardiology Devices 2011 (15 Countries) 21Data from FREEDOM-301 Study for LEVADEX™ Orally Inhaled Migraine Drug Published in 'Headache' 2Data from FREEDOM-301 Study for LEVADEX™ Orally Inhaled Migraine Drug Published in 'Headache' 3Data from FREEDOM-301 Study for LEVADEX™ Orally Inhaled Migraine Drug Published in 'Headache' 4
The Tag-It™ Cystic Fibrosis ASR reagents can be used by high complexity CLIA approved laboratories for detection of up to 70 mutations and 6 variants (polymorphisms) in the cystic fibrosis tran...
The Ultra HDL (UHDL) assay is used for the quantitation of high density lipoprotein (HDL) cholesterol in human serum or plasma....
... A histological embedment block ... This file system incorporates ... embedment block protection, simplified ... error and facilitation of ...
... The first instrumentation ... efficiently manage the ... Proven technology automatically ... collates cassettes sequentially. ...
Medicine Products: